Potashman, Michele H.
Mize, Miranda L.
Beiner, Melissa W.
Pierce, Samantha
Coric, Vladimir
Schmahmann, Jeremy D. http://orcid.org/0000-0003-0706-5125
Funding for this research was provided by:
National Ataxia Foundation
MINDLink Foundation
Biohaven Pharmaceuticals, Inc.
Article History
Accepted: 2 November 2022
First Online: 10 December 2022
Declarations
:
: Michele Potashman declares no conflict of interests. Her disclosures are that she is employed by and owns shares in Biohaven Pharmaceuticals. Miranda Mize declares no conflict of interests and has no disclosures. Melissa Beiner declares no conflict of interests. Her disclosures are that she is employed by and owns shares in Biohaven Pharmaceuticals. Samantha Pierce declares no conflict of interests and has no disclosures. Vladimir Coric declares no conflict of interests and discloses that he is employed by and owns shares in Biohaven Pharmaceuticals. Dr. Schmahmann declares no conflict of interests. His disclosures are that he is site PI for Biohaven NCT03701399, NCT02960893 and NCT03952806, consults for Medavante; receives royalties from Oxford University Press, Elsevier, MacKeith Press, and Springer; and is the inventor of the Brief Ataxia Rating Scale, Cerebellar Cognitive Affective/Schmahmann Syndrome Scale, the Patient Reported Outcome Measure of Ataxia, and the Cerebellar Neuropsychiatry Rating Scale which are licensed to the General Hospital Corporation.